Literature DB >> 7969046

Mechanisms of resistance to ansamycin antibiotics in human breast cancer cell lines.

M N Benchekroun1, E Schneider, A R Safa, A J Townsend, B K Sinha.   

Abstract

We recently reported that multidrug-resistant, P-170 glycoprotein-positive, Adriamycin-selected, human breast tumor (MCF7/ADRR) cells were resistant to the benzoquinonoid ansamycin antibiotics geldanamycin (GL) and herbimycin A (HA) and that significantly fewer hydroxyl radicals were formed in resistant cells. We have carried out additional studies to define the mechanisms of cytotoxicity of and resistance to GL and HA, by directly examining the interactions of these drugs with P-170 glycoprotein using photoaffinity labeling. We found that both GL and HA inhibited binding of azidopine to P-170 glycoprotein in a dose-dependent manner. We have developed a 10-fold GL-resistant cell line (MCF7/GLR) by continuous drug exposure. Our studies indicated no significant differences in free radical formation between wild-type MCF7 cells and MCF7/GLR cells. Uptake and efflux studies indicated a small decrease in the GL accumulation but no difference in the efflux of GL in these cells. Verapamil had no effect on cellular accumulation of GL in wild-type MCF7 cells or MCF7/GLR cells. Verapamil significantly increased the accumulation of GL in MCF7/ADRR cells and enhanced GL cytotoxicity 12-fold, suggesting that GL interacted with the P-170 glycoprotein. Using reverse transcription-polymerase chain reaction, we found no expression of the mdr1 gene; however, expression of the multidrug resistance-associated protein was about 2-fold higher in MCF7/GLR cells. Taken together, these studies indicate that the mechanisms of GL resistance are multifactorial. Although decreased free radical formation may not play a significant role in low levels of GL resistance, e.g., in MCF7/GLR cells, both overexpression of mdr1 and decreased free radical formation contribute to GL resistance in highly resistant cells such as MCF7/ADRR cells.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7969046

Source DB:  PubMed          Journal:  Mol Pharmacol        ISSN: 0026-895X            Impact factor:   4.436


  16 in total

Review 1.  Geldanamycin: the prototype of a class of antitumor drugs targeting the heat shock protein 90 family of molecular chaperones.

Authors:  H J Ochel; K Eichhorn; G Gademann
Journal:  Cell Stress Chaperones       Date:  2001-04       Impact factor: 3.667

2.  Activity of doxorubicin covalently bound to a novel human serum albumin microcapsule.

Authors:  M Eatock; N Church; R Harris; W Angerson; C McArdle; R French; C Twelves
Journal:  Invest New Drugs       Date:  1999       Impact factor: 3.850

3.  Congenital expression of mdr-1 gene in tissues of carcinoma and its relation with pathomorphology and prognosis.

Authors:  Li-Jian Zhang; Ke-Neng Chen; Guang-Wei Xu; Hai-Ping Xing; Xiao-Tian Shi
Journal:  World J Gastroenterol       Date:  1999-02       Impact factor: 5.742

4.  Ganetespib (STA-9090), a nongeldanamycin HSP90 inhibitor, has potent antitumor activity in in vitro and in vivo models of non-small cell lung cancer.

Authors:  Takeshi Shimamura; Samanthi A Perera; Kevin P Foley; Jim Sang; Scott J Rodig; Takayo Inoue; Liang Chen; Danan Li; Julian Carretero; Yu-Chen Li; Papiya Sinha; Christopher D Carey; Christa L Borgman; John-Paul Jimenez; Matthew Meyerson; Weiwen Ying; James Barsoum; Kwok-Kin Wong; Geoffrey I Shapiro
Journal:  Clin Cancer Res       Date:  2012-07-17       Impact factor: 12.531

5.  Hsp90 inhibition: elimination of shock and stress.

Authors:  Adam S Duerfeldt; Brian S J Blagg
Journal:  Bioorg Med Chem Lett       Date:  2010-07-01       Impact factor: 2.823

6.  P-Glycoprotein-mediated resistance to Hsp90-directed therapy is eclipsed by the heat shock response.

Authors:  Andrea K McCollum; Cynthia J TenEyck; Bridget Stensgard; Bruce W Morlan; Karla V Ballman; Robert B Jenkins; David O Toft; Charles Erlichman
Journal:  Cancer Res       Date:  2008-09-15       Impact factor: 12.701

Review 7.  Hydrating for resistance to radicicol.

Authors:  Adam S Duerfeldt; Brian S J Blagg
Journal:  ACS Chem Biol       Date:  2009-04-17       Impact factor: 5.100

8.  Cell-cycle arrest and p53 accumulation induced by geldanamycin in human ovarian tumour cells.

Authors:  A J McIlwrath; V G Brunton; R Brown
Journal:  Cancer Chemother Pharmacol       Date:  1996       Impact factor: 3.333

Review 9.  Contributions of co-chaperones and post-translational modifications towards Hsp90 drug sensitivity.

Authors:  Annerleim Walton-Diaz; Sahar Khan; Dimitra Bourboulia; Jane B Trepel; Len Neckers; Mehdi Mollapour
Journal:  Future Med Chem       Date:  2013-06       Impact factor: 3.808

10.  Acquired resistance to 17-allylamino-17-demethoxygeldanamycin (17-AAG, tanespimycin) in glioblastoma cells.

Authors:  Nathalie Gaspar; Swee Y Sharp; Simon Pacey; Chris Jones; Michael Walton; Gilles Vassal; Suzanne Eccles; Andrew Pearson; Paul Workman
Journal:  Cancer Res       Date:  2009-02-24       Impact factor: 12.701

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.